1.0550
26-十一月-24 11:10:46
15 分钟延时
股票
-0.0450
-4.09%
今日范围
1.0400 - 1.1143
ISIN
N/A
来源
NASDAQ
Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021
11 2月 2021 09:12:54 条件 Nasdaq GlobeNewswire
Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase
20 1月 2021 07:00:00 条件 Nasdaq GlobeNewswire
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
06 1月 2021 07:00:01 条件 Nasdaq GlobeNewswire